Last reviewed 2026-06-11 · How we verify

Adjunct Therapy to Achieve Long-term Asthma Control — Treatment Landscape & Competitive Intelligence

Adjunct Therapy to Achieve Long-term Asthma Control (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Adjunct Therapy to Achieve Long-term Asthma Control, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Fundacio Privada Mon Clinic Barcelona · 1 drug in Adjunct Therapy to Achieve Long-term Asthma Control
2. Novartis · 1 drug in Adjunct Therapy to Achieve Long-term Asthma Control

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Adjunct Therapy to Achieve Long-term Asthma Control:

• Adjunct Therapy to Achieve Long-term Asthma Control treatment updates — RSS
• Adjunct Therapy to Achieve Long-term Asthma Control treatment updates — Atom
• Adjunct Therapy to Achieve Long-term Asthma Control treatment updates — JSON

Cite this brief

Drug Landscape (2026). Adjunct Therapy to Achieve Long-term Asthma Control — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adjunct-therapy-to-achieve-long-term-asthma-control. Accessed 2026-06-11.

Related

• Adjunct Therapy to Achieve Long-term Asthma Control full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing